Home » Stocks » PDSB

PDS Biotechnology Corporation (PDSB)

Stock Price: $2.83 USD 0.07 (2.54%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $2.85 +0.02 (0.71%) Jan 22, 6:17 PM
Market Cap 63.00M
Revenue (ttm) n/a
Net Income (ttm) -15.00M
Shares Out 18.96M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $2.83
Previous Close $2.76
Change ($) 0.07
Change (%) 2.54%
Day's Open 2.76
Day's Range 2.69 - 2.85
Day's Volume 189,533
52-Week Range 0.65 - 4.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment

GlobeNewsWire - 2 weeks ago

FLORHAM PARK, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious dise...

GlobeNewsWire - 2 weeks ago

FLORHAM PARK, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious dise...

GlobeNewsWire - 1 month ago

FLORHAM PARK, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious dise...

Insider Monkey - 1 month ago

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...

GlobeNewsWire - 2 months ago

Granted methods patent for Versamune® platform by the United States Patent and Trademark Office Granted methods patent for Versamune® platform by the United States Patent and Trademark Office

Seeking Alpha - 2 months ago

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency PDS0203 prioritized for clinical development by PDS Bio...

GlobeNewsWire - 2 months ago

VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients VERSATILE-002 Trial for First L...

GlobeNewsWire - 2 months ago

FLORHAM PARK, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious dise...

GlobeNewsWire - 2 months ago

PDS Biotech progresses second Phase 2 human clinical trial of PDS0101 PDS Biotech progresses second Phase 2 human clinical trial of PDS0101

GlobeNewsWire - 3 months ago

FLORHAM PARK, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious dise...

GlobeNewsWire - 3 months ago

FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel ...

GlobeNewsWire - 4 months ago

FLORHAM PARK, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel ...

GlobeNewsWire - 4 months ago

FLORHAM PARK, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious di...

GlobeNewsWire - 5 months ago

FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing n...

Seeking Alpha - 5 months ago

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious di...

GlobeNewsWire - 5 months ago

FLORHAM PARK, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel c...

GlobeNewsWire - 5 months ago

FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel c...

GlobeNewsWire - 5 months ago

FLORHAM PARK, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious di...

GlobeNewsWire - 5 months ago

Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccination Versamune-CoV-2 (...

GlobeNewsWire - 6 months ago

PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS0201 for tuberculosis and PDS0203 for COVID-19 PDS Biotech ramps up third infectious disease ...

Forbes - 6 months ago

As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you t...

Other stocks mentioned: BCRX, ECOR, TTPH, CRDF
GlobeNewsWire - 7 months ago

NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020 NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020

GlobeNewsWire - 7 months ago

Brazilian government to provide initial funding support to progress development of Versamune®-based vaccine to prevent COVID-19 infection

GlobeNewsWire - 7 months ago

FLORHAM PARK, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious di...

GuruFocus - 7 months ago

Wall Street sell-side analysts have issued buying recommendation ratings for shares of PDS Biotechnology Corp (NASDAQ:PDSB) and Hoth Therapeutics Inc (NASDAQ:HOTH), even though these stocks ha...

Other stocks mentioned: HOTH
GlobeNewsWire - 7 months ago

FLORHAM PARK, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious di...

Seeking Alpha - 8 months ago

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

FLORHAM PARK, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious dis...

GlobeNewsWire - 8 months ago

NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents NCI to study PDS0103, in addition to planned Phase 2 clinical e...

GlobeNewsWire - 9 months ago

Expanded infectious disease program to address current and potential pandemics builds on existing tuberculosis collaboration

GlobeNewsWire - 9 months ago

PRINCETON, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies...

Zacks Investment Research - 9 months ago

PDS Biotechnology (PDSB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 9 months ago

PRINCETON, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’...

GlobeNewsWire - 10 months ago

PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s...

GlobeNewsWire - 10 months ago

PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s...

GlobeNewsWire - 11 months ago

PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s...

GlobeNewsWire - 11 months ago

PRINCETON, N.J., Feb. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies ...

About PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, ... [Read more...]

Industry
Biotechnology
CEO
Frank Bedu-Addo
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
PDSB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is 6.62, which is an increase of 133.92% from the latest price.

Price Target
$6.62
(133.92% upside)
Analyst Consensus: Strong Buy